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Abstract
Background: Short hairpin RNA (shRNA) is an established and effective tool for stable knock down of gene expression.
Lentiviral vectors can be used to deliver shRNAs, thereby providing the ability to infect most mammalian cell types with
high efficiency, regardless of proliferation state. Furthermore, the use of inducible promoters to drive shRNA expression
allows for more thorough investigations into the specific timing of gene function in a variety of cellular processes.
Moreover, inducible knockdown allows the investigation of genes that would be lethal or otherwise poorly tolerated if
constitutively knocked down. Lentiviral inducible shRNA vectors are readily available, but unfortunately the process of
cloning, screening, and testing shRNAs can be time-consuming and expensive. Therefore, we sought to refine a popular
vector (Tet-pLKO-Puro) and streamline the cloning process with efficient protocols so that researchers can more efficiently
utilize this powerful tool.
Methods: First, we modified the Tet-pLKO-Puro vector to make it easy (“EZ”) for molecular cloning (EZ-Tet-pLKO-Puro).
Our primary modification was to shrink the stuffer region, which allows vector purification via polyethylene glycol
precipitation thereby avoiding the need to purify DNA through agarose. In addition, we generated EZ-Tet-pLKO vectors
with hygromycin or blasticidin resistance to provide greater flexibility in cell line engineering. Furthermore, we provide a
detailed guide for utilizing these vectors, including shRNA design strategy and simplified screening methods.
Results: Notably, we emphasize the importance of loop sequence design and demonstrate that the addition of a single
mismatch in the loop stem can greatly improve shRNA efficiency. Lastly, we display the robustness of the system with a
doxycycline titration and recovery time course and provide a cost/benefit analysis comparing our system with purchasing
pre-designed shRNA vectors.
Conclusions: Our aim was twofold: first, to take a very useful shRNA vector and make it more amenable for molecular
cloning and, secondly, to provide a streamlined protocol and rationale for cost-effective design, cloning, and screening of
shRNAs. With this knowledge, anyone can take advantage of this powerful tool to inducibly knockdown any gene of their
choosing.
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Background
Knockdown of gene expression at the mRNA level via RNA
interference (RNAi) is a common method for investigating
gene function. For transient knockdown in mammalian cell
culture, small interfering RNA (siRNA) is often favored.
The benefits of siRNA include commercially available RNA
oligos which can be transfected into cells for quick and
efficient knockdown. However, siRNA becomes less useful
when working with cell types with low transfection
efficiency or in experiments that require prolonged gene
knockdown [1]. Another common method for utilizing
RNAi is short-hairpin RNA (shRNA), synthetic non-coding
RNA that utilizes the endogenous microRNA machinery to
process functional RNAi. Though not as simple to use as
siRNA, shRNA can avoid concerns of low transfection
efficiency and temporary knockdown by using retroviral
delivery and selection for stable genomic integration [2–4].
Lentiviral shRNA vectors are popular due to their ability
to infect nearly any cell type and integrate into the genome
of both dividing and non-dividing cells. In 2006, the
BROAD institute established the RNAi Consortium to
identify and clone multiple shRNA candidate sequences for
every gene in the mouse and human genomes [5]. The con-
sortium cloned the shRNA sequences into the pLKO
lentiviral vector backbone and has made them available for
distribution from GE Healthcare Dharmacon and Sigma-
Aldrich. The shRNAs were not all functionally validated
but were given a computationally calculated score for predi-
cated efficiency and specificity.
In 2009, Dmitri Wiederschain and colleagues built upon
the pLKO vector and made multiple changes, the two most
significant of which were the inclusion of the Tet-Repressor
gene (TetR) and an H1 promoter containing the TetOpera-
tor (TetO) sequence to drive shRNA expression. Together,
these modifications allow transcription of shRNA upon the
addition of tetracycline, or its analogue doxycycline (Dox),
to sequester TetR and relieve repression at the TetO [5, 6].
This vector combines the benefits of lentiviral delivery and
inducible gene knockdown, providing many advantages
over siRNA or constitutive shRNA. One key advantage is
the ability to use the same pool of cells for the controls (no
induction) and the test sample (plus inducer), thereby elim-
inating concerns of transfection/infection efficiency or un-
intentional clonal selection between ‘empty/non-targeting’
and ‘shRNA’ stable pools. By combining inducible vectors
with the list of candidate shRNA sequences from the RNAi
consortium it is now possible to induce knockdown of
nearly any gene in virtually any cell type.
The Tet-pLKO-Puro vector is a potentially powerful tool,
but the process of designing and cloning shRNAs into the
vector is not without challenge. In an effort to improve this
tool even further we made some modifications to make it
more amenable for cloning. Furthermore, we establish clear
and efficient protocols for designing and cloning shRNAs
into the vector. In addition, we demonstrate the importance
of loop design including using a single mismatch to im-
prove shRNA efficiency. With our modified vector (EZ-
Tet-pLKO) and a detailed description for designing and
cloning shRNAs, we aim to make it easy for anyone to
quickly adopt and utilize this tool.
Results
Modifications to the Tet-pLKO-Puro vector
We started with the Tet-pLKO-Puro vector and modified it
to make it more amenable for molecular cloning, terming
our version EZ-Tet-pLKO-Puro. First, we used mutagenesis
to delete the large non-functional stuffer region (~1.9 kb),
leaving a smaller stuffer of ~200 bp (Fig. 1a). Second, we
mutated the 5′ AgeI cloning site to an NheI sequence to
ameliorate occasional difficulties with inefficient AgeI +
EcoRI co-digestion. Additionally, we generated matching
vectors with mammalian selection markers for hygromycin
(Hygro) or blasticidin (Blast) resistance (Fig. 1a). The
smaller stuffer makes it possible to purify cut vector by
size-selective DNA precipitation with polyethylene glycol
(PEG). To compare precipitation methods, cut DNA was
precipitated by isopropanol, 8% PEG, or 6% PEG. The 6%
PEG precipitation removed nearly all of the 200 bp stuffer
(Fig. 1b). Together, the combination of vector modifications
and utilization of PEG precipitation provides a simplified
method for preparing cut vector.
shRNA oligo design
Developing functional shRNA constructs often requires
testing many targeting sequences; therefore, a process for
designing shRNAs quickly and efficiently is quite valuable.
Targeting sequences were selected as described in the
methods section and used to generate sense and antisense
shRNA oligos. shRNA oligos contain the following ele-
ments: 5′ overhang, targeting sequence, loop, reverse-
complement targeting sequence, transcriptional terminator
sequence, and 3′ overhang (Fig. 2a). The antisense oligo
(bottom strand) is a reverse complement of the sense oligo
with complementary overhangs. Without a mismatch, a
6 nt palindrome loop is predicted to collapse to a 4 nt loop
and shift the targeting sequence by one base (Fig. 2b). Im-
mortalized prostate epithelial cells (iPrECs) were infected
with shRNA lentivirus (sh.p38δ or sh.Creb1) and pools
were selected containing the same targeting sequence with
or without a single mismatch. Immunoblot showed very ef-
ficient knockdown of p38δ with the 7 nt loop and no
knockdown with the 6 nt loop (Fig. 2c). Probing for TetR
showed that both pools were infected with the lentivirus
and had similar expression levels of the lentiviral construct.
A similar test was performed using cells containing the
sh.Creb1 construct and produced similar results (Fig. 2d).
Thus, when designing shRNA sequences it is crucial to
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consider not only the targeting sequence, but also a mis-
match in the loop stem.
Streamlined colony screening
After ligation of vector and shRNA oligos the DNA must
be transformed into competent bacteria and colonies must
be screened. Colony-PCR is a quick way to use small
amounts of bacteria directly as template in a PCR reaction.
We designed primers to span the stuffer/shRNA insert re-
gion, producing a ~450 bp band for positive clones and a
~620 bp band for background vector with retained stuffer
(Fig. 3a). PCR product was visualized by agarose gel
electrophoresis, which produced clearly identifiable bands
for true clones and background colonies (Fig. 3b).
Additionally, clones can be further validated by restriction
enzyme (RE) digest screening, which requires a miniprep
step to isolate plasmid DNA. The original Tet-pLKO-Puro
protocol recommended using an XhoI loop in the hairpin
[6, 7]. Because there are already 3 XhoI sites in the parental
EZ- Tet-pLKO vector (Fig. 3c-i), introducing a fourth XhoI
site in the loop creates four fragments upon digestion
(Fig. 3c-ii, d). Furthermore, in the EZ-Tet-pLKO vector two
of these bands are so small, 138 bp (***) and 43 bp (****),
representing less than 2% of the total DNA (Fig. 3c-ii, d)
Fig. 1 Vector maps and PEG purification. a Basic vector maps (not to scale) for the original Tet-pLKO-Puro vector and our modified versions. b Agarose
gel electrophoresis comparing DNA precipitation methods. 10 μg of EZ-Tet-pLKO vector DNA was co-digested with NheI + EcoRI. The digest was split
into three 3 μg aliquots and precipitated with isopropanol (Iso) or polyethylene glycol (PEG) at 6 or 8% concentration. 1 μg of control DNA (uncut and
cut) was run alongside 1/3 of the precipitated DNA samples
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making it very difficult to visualize on an agarose gel even
with a long exposure (Fig. 3e). As a way to simplify and im-
prove the RE screening process, we recommend a SpeI site
for loop design (Fig. 3c-iii). When visualized on agarose, a
positive SpeI screen produces a clear band at ~500 bp,
which is ~5% of total DNA and easily detectable (Fig. 3d, e).
We further validated the EZ-Tet-pLKO-shRNA positive
clones by Sanger sequencing using the same pLKO-fwd pri-
mer as used in the PCR screen. Thus, the combination of
colony-PCR as a cheap and quick primary screen and SpeI-
based digest as a secondary screen creates a streamlined
process for identifying positive shRNA clones.
Dox Titration and recovery time courses
Next, we validated the efficacy of the EZ-Tet-pLKO-
Puro vector in cell culture. Cells were infected with
lentivirus and pools were selected with puromycin. We
performed a titration with Dox (0.5 to 50 ng/mL) and
found that as little as 10 ng/mL was sufficient to induce
target (p38α) knockdown (Fig. 4a). Furthermore, the tar-
get protein can be recovered after removal of Dox. Cells
with sh.p38α were treated with Dox for 72 h and then
split. Dox was removed and samples were harvested over
a recovery time course (Fig. 4b). Recovery of protein
began four days after removal of Dox. Thus, the EZ-Tet-
pLKO system is both inducible and reversible.
Cost analysis and comparison
Our method for designing, cloning, screening, and validat-
ing lentiviral shRNAs is not only efficient but also cost
effective. Most reagents can be found in a standard molecu-
lar biology lab (e.g., restriction enzymes, PCR reagents,
agarose gel electrophoresis equipment). The EZ-Tet-pLKO
plasmids can be acquired from the Addgene repository.
The only reagent that is single-use are the shRNA oligos,
which are unique for each clone and also the largest single
cost. However, once the required reagents are assembled, it
only costs ~ $50 in supplies and materials for each new
shRNA cloned (Table 1).
Estimated costs for the various reagents needed in the
cloning protocol. Note: Does not include plastic consum-
ables or common lab reagents (e.g., LB media, alcohol, agar-
ose, competent cells) or lentiviral packaging components.
Estimated total cost is based on screening 10 colonies per
shRNA ligation. The primary cost for subsequent shRNAs
are the sense and anti-sense oligos ($44), with the remaining
cost coming from consumable enzymes. PNK: Polynucleo-
tide Kinase. AP: Antarctic Phosphatase. IDT: Integrated
DNATechnologies. NEB: New England BioLabs.
In addition to the method described here, it is also pos-
sible to purchase shRNAs already cloned in lentiviral plas-
mids from an RNAi Consortium library, such as Sigma
Aldrich or Dharmacon. The costs and benefits to using our
custom design method vs purchasing vectors (Table 2) out-
weigh the others. The primary benefits of our method are
the low costs and customizability, the ability to use the im-
proved 7 nt loop, and use of any of three different selection
vectors (Puro, Hygro, or Blast). The alternative options are
to purchase shRNAs already cloned into a vector at a cost
of $50–$100 (non-inducible) or $400–$450 (Dox inducible),
Fig. 2 shRNA oligo design and loop comparison. a Format for shRNA oligo design. Upper strand is sense oligo, lower strand is anti-sense oligo.
b Diagram of predicted shRNA loop structure with a basic SpeI sequence (6 nt: ACUAGU) or including a single stem mismatch (7 nt: UACUAGU).
Colors correlate to calculated likelihood of the depicted pairing. See methods for details on prediction tool. c Immunoblot showing two different
pools of iPrEC cells with shRNA against p38δ, with the only difference being a single mismatch in the loop sequence of the shRNA. Cells were
treated −/+ Dox for 72 h. TetR was probed on a separate gel. p38α and Tubulin serve as loading controls. d Same experiment as c using a different
pair of shRNAs targeting Creb1. Cells were treated −/+ Dox for 5 days
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and they are limited to the 6 nt loop. In addition, lentiviral
particles can also be purchased which allows for immediate
infection but come at a high cost (> $1,000). Though the
commercial options may be quicker, the cost, customizabil-
ity, versatility, inducibility, and more efficient 7 nt loop of
the EZ-Tet-pLKO method makes it a better option overall.
Comparison of cost/benefits of our cloning method ver-
sus other sources of TRC (The RNAi Consortium) library
shRNAs. Note: Costs here are based on Dharmacon prices
(http://dharmacon.gelifesciences.com/applications/rna-inter
ference/shrna/, last accessed Dec. 6th, 2016).
Efficiency
The large stuffer (1.9 kb) region between the cloning sites
in the original Tet-pLKO-Puro vector necessitated the tedi-
ous process of gel purifying the vector fragment. By redu-
cing the stuffer to 200 bp we were able to more efficiently
and quickly isolate the purified cut vector with PEG. Use of
the original vector with the long stuffer resulted in the same
number of colonies in the vector-only ligated plate as on
the insert ligation plate, necessitating excessive screening of
>50 colonies to find 1 transformant with the insert (i.e.,
2%). With the shorter stuffer, there were typically ~0–20
Fig. 3 Screening techniques. a Diagram showing expected products from PCR screening pLKO ligation-transformed colonies. b Agarose gel (2%) with a
positive and negative PCR product. c Vector maps (not to scale) with XhoI and SpeI restriction digest sites labeled in bp. Asterisks indicate corresponding
bands in Fig. 3d and e. d Diagram showing expected DNA fragments and relative intensity on gel from an XhoI (blue) vs SpeI (red) shRNA loop restriction
digest screen of the plasmids shown in 3c (i - parental EZ- Tet-pLKO vector with stuffer (Vec + stuff), ii - EZ-Tet-pLKO with shRNA XhoI loop (Vec + sh(X)), iii -
EZ-Tet-pLKO with shRNA SpeI loop (Vec + sh(S)). (*) is the predicted 348 bp XhoI fragment spanning the stuffer region in the original Tet-pLKO vector (i).
In the EZ-Tet-pLKO vector harboring an shRNA with an XhoI site in the loop (ii), XhoI digestion will generate three small fragments, 190 bp (**), 138 bp
(***), and 43 bp (****). In the EZ-Tet-pLKO vector harboring an shRNA with an SpeI site in the loop (iii), SpeI digestion will generate a clearly visible
diagnostic 500 bp fragment. e Agarose gel (2%) with XhoI or SpeI shRNA screens of constructs indicated in 3c (i, ii, iii). Each lane was
loaded with 4 μg of digested DNA. Bottom image shows lower part of the same gel with a longer exposure to show the barely detectable
43 bp (****) fragment
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colonies on the vector-only ligation plate and >20–100 col-
onies on the insert ligation plate, equating to an efficiency
of ~10–50 colonies per ng of cut vector (# colonies × 1000/
100 (LB dilution) × 20/4 (ligation reaction dilution) × 1/100
(ng vector DNA per μL ligation reaction). Furthermore,
~80% of these colonies had the desired insert. In addition,
the shorter stuffer allows for improved PCR screening and
saves at least a day by not having to wait to grow up the
colonies before standard restriction enzyme screening.
Discussion
The EZ-Tet-pLKO vector together with our detailed
methods provides a descriptive guide to efficiently utilize
inducible shRNAs. Though we have focused on a modi-
fied pLKO vector, the principles of shRNA design and
screening could be applied to many other cloning sce-
narios. Our primary modification to the vector was to
shrink the stuffer region. The stuffer is non-functional
DNA, and we chose to keep a small 200 bp region so
that double-cut vector could clearly be visualized separ-
ately from linearized single-cut vector on agarose. More-
over, retaining a small stuffer allows for size-selective
precipitation of cut vector via PEG [8]. Compared to al-
cohol precipitation and gel extraction, PEG precipitation
is faster, provides cleaner DNA, and avoids concerns of
potential DNA damage from UV exposure [9, 10]. We
also sought to emphasize the importance of using a
proper loop design for shRNAs including adding a stem
mismatch [11]. The inclusion of a mismatch in the loop
region can aid hairpin formation by preventing loop col-
lapse and thus shifting the targeting sequence, which
can disrupt proper DICER binding and target mRNA
cleavage [12, 13]. The mismatch was not always neces-
sary for proper shRNA function (not shown), but in at
least the two cases reported here it was crucial and
should always be included to maximize the chances of
developing a successful shRNA construct.
Though we sought to make our protocol as easy as pos-
sible, there are some potential areas of difficulty that may
be avoided by taking extra precautions. One critical detail is
that the DNA pellet precipitated by PEG can often be invis-
ible, so extra caution should be taken when decanting the
supernatant after centrifugation. If recovery is consistency
low, consider trying 7 and 8% PEG precipitations to
increase precipitation efficiency at the tradeoff for slightly
more stuffer retention. When transforming the ligation into
bacteria, it is important to use recombination-deficient
E.coli strains (such as NEB-Stable) in order to minimize
unwanted recombinations due to lentiviral LTR sequences.
When sequencing clones, be aware that shRNA hairpin
sequences can sometimes cause early termination when
read by Sanger sequencing and may (but not always)
require the use of specialized sequencing protocols for
dealing with RNAi constructs [14, 15]. Lastly, freshly
prepared lentivirus is preferred when infecting cells, though
frozen virus can be used with ~50% decrease in infectivity
for each freeze-thaw cycle.
One important caveat with the Dox-inducible system
is that at high doses (>1 μg/mL), Dox can have detri-
mental effects on cell viability via disruption of mito-
chondrial function [16]. In our experience, we observed
viability effects from prolonged treatment (>4 days) at
500 ng/mL but saw no effects from a 2-week treatment
at 50 ng/mL (not shown). As an extra control, the par-
ent cell line (without lentiviral infection) can be treated
with Dox to check specifically for effects on cell viability.
In most cases a 10–50 ng/mL dose of Dox should be
Fig. 4 Dox titration and recovery. a Immunoblot showing Dox titration with iPrECs containing EZ-Tet-pLKO-sh.p38α. Cells were treated with Dox
for 72 h and lysed. Note: the lower band (arrow pointing) is p38α. b Cells were treated −/+ Dox (50 ng/mL) for 72 h. At that time, two samples
were lysed (72 h pre-treated) while another plate of treated cells was split and allowed to recover without Dox for 1–8 days. Note: due to changes in
confluency, the ‘pre-treated’ cells have higher basal level of p38 (α and δ) than at day 8
Table 1 Reagent cost analysis
Reagent Cost Source
EZ-Tet-pLKO plasmid $65 Addgene
PEG-8000 $38 (per 250 g) Sigma
shRNA oligo (sense/antisense) $22 (ea.) IDT
Screening primer (Fwd/Rev) $8 (ea.) IDT
Cloning enzymes (PNK, AP,
ligase)
$2.50 (per ligation) NEB, Affymetrix
Restriction enzymes $0.25 (per digest) NEB
PCR reagents $0.25 (per reaction) Empirical Bioscience
Total cost to clone first shRNA ~$170
Cost per subsequent shRNA ~$50
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well tolerated but that should be tested by the end user
in their particular cell line as a precaution.
The timing of gene knockdown and recovery is not
universal. For most genes 72 h is sufficient to see knock-
down at the protein level. However, this is highly
dependent on protein stability. Longer-lived proteins
(e.g., membrane-bound receptors, housekeeping pro-
teins) may take up to a week for proper knockdown. We
observed p38α knockdown at 72 h, but Creb1 knock-
down was not observed until at least day five of Dox in-
duction. Likewise, protein recovery will be highly
dependent on the transcription rate of the gene so that
lower expressed genes will take longer to recover. Fur-
thermore, cell confluency and proliferation rate will also
affect the rate of protein synthesis and turnover, thus af-
fecting Dox knockdown and recovery timing. All these
factors need to be considered when designing
temporally-sensitive experiments and will be cell and
context specific.
When testing new shRNA constructs, transduced cells
lines need to be validated. Knockdown at the mRNA
level can usually be seen by qRT-PCR at 24–48 h. How-
ever, as previously mentioned, protein knockdown can
take up to five days or longer potentially. A good control
to include when testing new pools is to probe an immu-
noblot for the TetR protein to confirm that the selected
pool of cells has robust expression of the lentiviral
vector. Likewise, if comparing pools or clones, those
with highest TetR expression often show the greatest
knockdown (not shown). When targeting a new gene,
we recommend starting with at least three different tar-
geting sequences with the expectation that one or two
will work efficiently.
Lastly, we also sought to aid researchers by designing
Hygro and Blast resistant variants of the EZ-Tet-pLKO
vector, thus providing more flexibility in creating mul-
tiple genetic engineered cell lines. By combining all three
vectors in one cell line it would be possible to knock-
down two or three targets simultaneously upon Dox
treatment. In addition to the Tet inducible system, there
are other inducible shRNA vectors that can prove useful
and are commercially available, such as cumate or
IPTG-inducible vectors [17, 18]. With some creativity
and strategy it would also be possible to create cells with
multiple shRNAs, each activated by different inducers.
Moreover, inducible shRNAs could be combined with
inducible cDNA expression systems to test overexpres-
sion and knockdown simultaneously or sequentially [19].
Use of inducible vectors with various selection markers
opens the door for greater quantity and variety of ques-
tions that can be addressed with molecular biology.
Conclusions
Inducible shRNAs are a very powerful tool when used
properly. We sought to provide a guide to allow more
people to more easily use this system with our EZ-Tet-
pLKO vector. There are lots of ways to manipulate gene
expression, including the recent advent of CRISPR/Cas9
technologies. Though the potential of CRISPR is great, it
is not without serious limitations, including inability to
study genes with lethal knockdown phenotypes and the
reliance on selecting clonal populations for cell culture
studies [20]. In addition to the cell culture uses shown
here, the pLKO system is also useful in vivo, for example
with tumor xenografts which can be induced to knock-
down a gene upon addition of Dox to the animal food or
water [21]. Our goal with this report was to take the
already proven Tet-pLKO-Puro system and refine it fur-
ther. With these new EZ-Tet-pLKO vectors and proto-
cols, researchers will find this tool to be more versatile
and user-friendly than ever.
Methods
pLKO vector modifications
The Tet-pLKO-Puro plasmid was ordered from Addgene
(Plasmid 21915) [6, 7]. Mutagenesis was performed
using the QuikChange II Site Directed Mutagenesis kit
(Aligent). Bases 222–1869 of the stuffer region between
the AgeI and EcoRI cloning sites were deleted. The dele-
tion was performed by inserting an EcoRI site at base
222 of the stuffer (primer 5′- GCTACTCCACCACTT
GAATTCCTAAGCGGTCAGC). The vector was then
digested with EcoRI, re-ligated, and clones were screened
for those that ligated the new EcoRI site directly to
Table 2 Cost/benefit comparison of lentiviral shRNA methods
Method Cost Unit Benefits Drawbacks
EZ-Tet-pLKO $50 per shRNA Low cost, Customizable,
Puro/Hygro/Blast
Efficient 7 nt loop
2–3 day process
TRC library (non-inducible) $208/$330
(glycerol stock)
per shRNA/Set of 3–6 No cloning required Non-inducible, 6 nt loop
TRC library (Dox-inducible) $450/$1100
(glycerol stock)
per shRNA/ Set of 3 No cloning required High cost, 6 nt loop
$1195
(viral particles)
1 unique or 3 mixed Ready to use
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the 3′ cloning site, thus excising the bulk of the stuffer re-
gion and preserving the 3′ cloning site. Mutagenesis was
then used to mutate the AgeI restriction site to an NheI
sequence (primer 5′- TATCAGTGATAGAGACGCTAG
CGTGTTGTAAATGAGCA). The EZ-Tet-pLKO-Hygro
vector was made by PCR subcloning the Hygro resistance
gene from the pGL4.15 vector (Promega) using the follow-
ing primers: 5′-ATTATGGATCCATGAAGAAGCCCG
AACTC and 5′- ATTATGACGTCTTAAACTCGACC
TACCTC. The EZ-Tet-pLKO-Blast construct was made
by PCR subcloning the Blast resistance gene from pLenti-
CMV-rtTA3-Blast (Addgene 26429). For PCR cloning, in-
serts were amplified with Q5 high fidelity polymerase
(NEB) and ligated into Tet-pLKO-Puro between the
BamHI and AatII RE sites. All experiments were carried
out with the Puro variant.
Vector digest and PEG precipitation
Vector can be prepared by co-digesting EZ-Tet-pLKO-
Puro DNA with NheI and EcoRI (NEB). A typical digest
consisted of 5 μg of vector DNA with 20 u of each en-
zyme in a 50 μL digest volume for at least 3 h at 37 °C.
Cut vector was then dephosphorylated with Antarctic
Phosphatase (NEB) using the manufacturer’s protocol
and supplementing the 50 μL digest reaction with AP
buffer, enzyme, and water to make a 60 μL reaction vol-
ume. Cut vector was then diluted with water to a 200 μL
volume in a 1.5 mL Eppendorf tube. PEG was used to
precipitate the DNA and exclude the 200 bp excised
stuffer. We first prepared 2× stock of 12% (w/v) PEG-
8000 and 20 mM Magnesium Chloride. The 2× stock
was then added 1:1 to the cut and dephosphorylated
DNA sample. The DNA/PEG mixture was gently mixed
by inverting the tube a few times and left to sit at room
temperature for at least 1 h. After the incubation, the
DNA was centrifuged at 15,000 RCF in a bench top cen-
trifuge (Eppendorf 5415D) for 40 min. The length of the
incubation and spin are critical; any less time can greatly
decrease recovery. Next, 500 μL of 70% ethanol was
added to wash the DNA pellet, which was then spun
again for 5–10 min. The ethanol was then aspirated and
the wash was repeated once more. After the second
wash the DNA pellet was allowed to air dry and then
suspended in water (typically ~50 μL). DNA was then
quantified by Qubit (Q32850, ThermoFisher). Accur-
ate quantification is important for successful cloning.
Typically DNA recovery following 6% PEG precipita-
tion is ~50%.
shRNA oligo design and loop prediction
shRNA targeting sequences were chosen from the BROAD
RNAi Consortium database (http://www.broadinstitute.org/
rnai/trc). shRNA targeting sequences (with RNAi consor-
tium ID) are as follows: p38α (TRCN0000196472), p38δ
(TRCN0000197043), Creb1 (TRCN0000226466). Oligos
were designed as described in Fig. 2 and ordered from Inte-
grated DNA Technologies. The RNA folding probability
values in Fig. 2 were calculated using RNAstructure soft-
ware (v5.7) by Reuter et al. [22] (http://rna.urmc.rochester.
edu/RNAstructure.html).
shRNA oligo preparation
Sense and antisense shRNA oligos were suspended at
100 μM in duplex buffer (100 mM Potassium Acetate,
30 mM HEPES, pH 7.5). Next, 20 μL (2 μ-mol) of each
oligo were combined and annealed using a thermalcycler
(Labnet TC9600-G) with a program set to start at 95 °C
and drop ~5°/min down to room temperature. Alter-
nately, DNA can be annealed by placing in a beaker of
boiling water and moved off the heater to cool slowly to
room temperature. The annealed oligos were then di-
luted with water to 360 μL total and precipitated with
ethanol (added 40 μL of 3 M sodium acetate and 1 mL
ethanol). DNA was centrifuged for 30 min at 15,000
RCF in a bench top centrifuge, washed twice with 70%
ethanol, and suspended in 500 μL water. Annealed oligo
DNA was then quantified by Qubit (Q32850, Thermo-
Fisher). Synthesized oligos do not contain phosphory-
lated overhangs, so annealed oligo was treated with T4
poly-nucleotide kinase (M0201, NEB) and heat inacti-
vated, according to the manufacturer’s protocol.
Ligation and transformation
Prepared vector (cut, dephosphorylated, and PEG puri-
fied) was diluted to a working concentration of ~20–
100 ng/μL if needed. Phosphorylated oligos were diluted
(from the heat-inactivated PNK reaction) to a 1 ng/μL
working concentration. Ligations were performed using
the LigateIT rapid ligase kit (78400, Affymetrix) with
100 ng vector DNA and an 8:1 insert:vector molar ratio.
A vector-only ligation was also prepared to control for
incompletely digested and/or re-ligated vector derived
colonies. Next, 2 μL of the ligation reactions were trans-
formed into Stbl3 (Life Technologies) or NEB-Stable
(NEB) chemically competent E. coli. Competent cells
were incubated on ice for 30 min with 4 μL of ligation
DNA, then heat shocked at 42 °C for 40 s and returned
to ice for 1 min. Then, 1 mL of LB media was then
added to the cells and they were allowed to recover at
37 °C for 30 min, after which time 100–200 μL was
plated on LB-agar plates containing 100 μg/mL ampicil-
lin and incubated 12–16 h at 37 °C.
PCR screen
Colony-PCR was used to screen bacteria for successfully
ligated clones. Primers used were as follows: pLKO-Fwd
5′- ATTAGTGAACGGATCTCGACGG; pLKO-rev 5′-
AACCCAGGGCTGCCTTGG. To set up the PCR
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reactions, first 15 μL of water was added to PCR tubes.
Colony inoculation was performed by touching a p10
pipette tip to a colony, then mixing it in the desired
PCR tube with the water, and then dotting ~1 uL on a
labeled fresh LB agar (+amp) plate to keep track of the
colony. A positive control is always included by adding
~ 1–10 ng of EZ-Tet-pLKO-Puro plasmid to 15 μL
water. PCR was performed using Emprical Bioscience
Taq and buffer (TP-MG-500). A master mix was made
containing (per reaction): 2.5 μL of 10× Taq Buffer,
0.2 μL of Taq enzyme, 2 μL of 25 mM magnesium chlor-
ide, 0.2 μL of each primer (fwd and rev, 100 μM stocks),
and 3.9 μL water. Then, 10 μL of the master mix was
then added to the 15 μL of inoculated water which
served as the template. Thermalcycler settings used were
as follows: 1× [95 °C for 2 min], 35× [95° for 30 s, 68 °C
for 45 s], 1× [72 °C for 1 min]. DNA was then run on
2% agarose for visualization with a DNA ladder (N3231
or N3232, NEB). Positive clones can then be further vali-
dated by RE screening or sent directly for Sanger se-
quencing using the pLKO-Fwd primer.
Restriction enzyme digest screen
Clones were minipreped by alkaline lysis. DNA was
digested using the SpeI restriction enzyme (NEB). A
standard reaction condition was ~3 μg of DNA digested
with 10 u of enzyme in a 50 μL reaction for at least 1 h
at 37 °C. Digest reaction (10–20 μL) was then run out
on a 2% agarose gel.
Cell culture
iPrEC cells were grown in KSFM with included supple-
ments (17005042, Gibco) and 30 u/mL Pen/Strep
(Gibco). For shRNA induction 50–100 ng/mL Dox
(Sigma) was used. HEK293FT cells were used for lenti-
virus production and maintained in DMEM (11995,
Gibco) with 2 mM L-glutamine, 10% fetal bovine serum
(FBS), and 30 u/mL Pen/Strep. During transfection and
infection, cells were grown without antibiotics and for
infection were grown with heat inactivated serum
(30 min at 56 °C) to avoid immune complement interfer-
ence. Cells were maintained at 37 °C with 5% CO2.
Virus production/infection
pLKO constructs were used to make lentivirus in
HEK293FT cells using the ViraPower system (K497500,
Invitrogen). One T75 flask was needed per viral con-
struct, which were first coated with 2 μg/mL PolyD ly-
sine in PBS for 1 h at 37 °C and then seeded with 5
million cells and left overnight at 37 °C. The next day,
cells were switched to antibiotic-free media with heat-
inactivated serum and transfected (Lipofectamine2000,
ThermoFisher) with packaging plasmids (5 μg each:
pLP1, pLP2, pVSV-G) and the desired pLKO construct
or a GFP lentiviral vector as control. At 24 h post-
transfection, media was changed to the target cell
media (without antibiotics). HEK293FT cells were
then returned to 37 °C for 48 h to produce viral par-
ticles. Viral media was collected in 15 mL conical
tubes and centrifuged for 10 min at 1500 RPM in a
swinging bucket centrifuge (Megafuge 1.0R) to pellet
cell debris. Next, the viral media was filtered by syr-
inge through a 0.45 μM, low protein binding filter
(28145–505, VWR). Cells were typically infected by
first adding half the volume with normal growth
media (no antibiotics, heat inactivated serum) and
half volume with the filtered viral media plus poly-
brene to a 5 μg/mL final concentration to improve
infection rate. Infected cells were incubated 48–72 h
and then given fresh growth media for 24–48 h be-
fore beginning selection. A lentivirus containing GFP
was used as a positive control for viral production/in-
fection and to estimate the percentage of infected
cells. GFP was detected by fluorescence microscopy
48–72 h after infection.
Immunoblot
Cells were lysed in MAPK lysis buffer (50 mM Tris,
pH 7.5, 0.5 mM EDTA, 50 mM NaF, 100 mM NaCl,
50 mM β-glycerol phosphate, 5 mM Sodium Pyrophos-
phate, 1% TritonX100) or RIPA lysis buffer (10 mM Tris,
pH 7.5, 1 mM EDTA, 158 mM NaCl, 0.1% SDS, 1%
Sodium Deoxycholate, 1% TritonX100). Cells were
chilled, washed, and then lysis buffer was added and
plates sat for 30 min on ice. Cells were then scrapped,
centrifuged, and protein was quantified by BCA assay
(Pierce). Equivalent amounts of 30–50 μg of denatured
protein per sample was run on Novex SDS polyacryl-
amide tris-glycine gels (Life Technologies). Protein was
then transferred onto PVDF membrane and blocked in
5% BSA/TBST for 1 h at room temp. Primary and sec-
ondary antibodies were diluted in blocking buffer.
Primary antibodies were probed either 2–3 h at room
temp or overnight at 4 °C while all secondary antibodies
were probed 1 h at room temp. Luminol chemilumines-
cence was used with a Bio-Rad Chemi-Doc imaging sys-
tem with CCD camera to image blots and analyzed on
Quantity One software v4.5.2. The following antibodies
were used: p38α at 1:2000 (CST 9218), p38δ at 1:1000
(Santa Cruz sc-136063), Tubulin at 1:10,000 (Sigma
T9026), Creb1 at 1:1000 (CST 4820), and TetR at 1:2000
(Clone Tech 631131).
Abbreviations
Dox: Doxycycline; FBS: Fetal bovine serum; iPrEC: Immortalized prostate
epithelial cell; PEG: Polyethylene glycol; RE: Restriction enzyme; Tet: Tetracycline;
TetO: Tet operator; TetR: Tet Repressor; TRC: The RNAi Consortium
Frank et al. BMC Biotechnology  (2017) 17:24 Page 9 of 10
Acknowledgements
The Tet-pLKO-Puro plasmid was a gift from Dmitri Wiederschain. McLane
Watson helped with the design of the EZ-Tet-pLKO-Hygro vector.
Funding
These studies were supported by funds from the National Cancer Institute of
the National Institutes of Health under award numbers R01CA154835
(VVS, CKM) and P30CA023074 (CKM), Department of Defense award number
W81XWH-14-1-0479 (SBF, CKM), Worldwide Cancer Fund # 11–0082, Van Andel
Research Institute, and University of Arizona. The content is solely the responsibility
of the authors and does not necessarily represent the official views of the National
Institutes of Health or the Department of Defense.
Availability of data and materials
The EZ-Tet-pLKO vectors and full sequence information are available in the
Addgene repository (www.addgene.org): EZ-Tet-pLKO-Puro (Addgene plasmid
85966), EZ-Tet-pLKO-Hygro (Addgene plasmid 85972), EZ-Tet-pLKO-Blast
(Addgene plasmid 85973).
Authors’ contributions
SBF was responsible for experimental design, analysis, execution, and writing
of the manuscript. VVS was responsible for generation and validation of
the iPrEC-sh.Creb1 cell lines. CKM was responsible for analysis, writing,
communication, and supervising the project. All authors read and approved the
final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Author details
1Laboratory of Integrin Signaling and Tumorigenesis, Van Andel Research
Institute, Grand Rapids, MI, USA. 2Genetics Program, Michigan State
University, East Lansing, MI, USA. 3Department of Cellular and Molecular
Medicine, University of Arizona Cancer Center, 1515 N. Campbell Ave, Tucson,
AZ 85724, USA.
Received: 8 June 2016 Accepted: 21 February 2017
References
1. Davidson BL, McCray Jr PB. Current prospects for RNA interference-based
therapies. Nat Rev Genet. 2011;12(5):329–40.
2. Hannon GJ. RNA interference. Nature. 2002;418(6894):244–51.
3. Fellmann C, Lowe SW. Stable RNA interference rules for silencing. Nat Cell
Biol. 2014;16(1):10–8.
4. Singer O, Verma IM. Applications of lentiviral vectors for shRNA delivery and
transgenesis. Curr Gene Ther. 2008;8(6):483–8.
5. Moffat J, Grueneberg DA, Yang X, Kim SY, Kloepfer AM, Hinkle G, Piqani B,
Eisenhaure TM, Luo B, Grenier JK, et al. A lentiviral RNAi library for human
and mouse genes applied to an arrayed viral high-content screen. Cell.
2006;124(6):1283–98.
6. Wiederschain D, Wee S, Chen L, Loo A, Yang G, Huang A, Chen Y, Caponigro
G, Yao YM, Lengauer C, et al. Single-vector inducible lentiviral RNAi system for
oncology target validation. Cell Cycle. 2009;8(3):498–504.
7. Wee S, Wiederschain D, Maira SM, Loo A, Miller C, DeBeaumont R, Stegmeier F,
Yao YM, Lengauer C. PTEN-deficient cancers depend on PIK3CB. Proc Natl
Acad Sci U S A. 2008;105(35):13057–62.
8. Lis JT, Schleif R. Size fractionation of double-stranded DNA by precipitation
with polyethylene glycol. Nucleic Acids Res. 1975;2(3):383–9.
9. Cariello NF, Keohavong P, Sanderson BJ, Thilly WG. DNA damage produced
by ethidium bromide staining and exposure to ultraviolet light. Nucleic
Acids Res. 1988;16(9):4157.
10. Grundemann D, Schomig E. Protection of DNA during preparative agarose
gel electrophoresis against damage induced by ultraviolet light. BioTechniques.
1996;21(5):898–903.
11. Li L, Lin X, Khvorova A, Fesik SW, Shen Y. Defining the optimal parameters
for hairpin-based knockdown constructs. RNA. 2007;13(10):1765–74.
12. McIntyre GJ, Fanning GC. Design and cloning strategies for constructing
shRNA expression vectors. BMC Biotechnol. 2006;6:1.
13. Gu S, Jin L, Zhang Y, Huang Y, Zhang F, Valdmanis PN, Kay MA. The loop
position of shRNAs and pre-miRNAs is critical for the accuracy of dicer
processing in vivo. Cell. 2012;151(4):900–11.
14. Guo Y, Liu J, Li YH, Song TB, Wu J, Zheng CX, Xue CF. Effect of vector-
expressed shRNAs on hTERT expression. World J Gastroenterol. 2005;11(19):
2912–5.
15. Devroe E, Silver PA. Retrovirus-delivered siRNA. BMC Biotechnol. 2002;2:15.
16. Moullan N, Mouchiroud L, Wang X, Ryu D, Williams EG, Mottis A, Jovaisaite
V, Frochaux MV, Quiros PM, Deplancke B, et al. tetracyclines disturb
mitochondrial function across eukaryotic models: a call for caution in
biomedical research. Cell Rep. 2015;10(10):1681–91.
17. Mullick A, Xu Y, Warren R, Koutroumanis M, Guilbault C, Broussau S, Malenfant
F, Bourget L, Lamoureux L, Lo R, et al. The cumate gene-switch: a system for
regulated expression in mammalian cells. BMC Biotechnol. 2006;6:43.
18. Chen Q, Gao S, He W, Kou X, Zhao Y, Wang H, Gao S. Xist repression shows
time-dependent effects on the reprogramming of female somatic cells to
induced pluripotent stem cells. Stem Cells. 2014;32(10):2642–56.
19. Hodkinson PS, Elliott PA, Lad Y, McHugh BJ, MacKinnon AC, Haslett C, Sethi
T. Mammalian NOTCH-1 activates beta1 integrins via the small GTPase R-
Ras. J Biol Chem. 2007;282(39):28991–9001.
20. Zhang F, Wen Y, Guo X. CRISPR/Cas9 for genome editing: progress, implications
and challenges. Hum Mol Genet. 2014;23(R1):R40–6.
21. Chin YR, Yoshida T, Marusyk A, Beck AH, Polyak K, Toker A. Targeting Akt3
signaling in triple-negative breast cancer. Cancer Res. 2014;74(3):964–73.
22. Reuter JS, Mathews DH. RNAstructure: software for RNA secondary structure
prediction and analysis. BMC Bioinf. 2010;11:129.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Frank et al. BMC Biotechnology  (2017) 17:24 Page 10 of 10
